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severity is a common source of bias. Consequently, failure to properly control for the 
bias could lead to serious ﬂ aws in the study. METHODS: We used a novel approach 
for identifying comorbidities associated with COPD by mapping the incident comor-
bidity patterns in the pre-COPD diagnosis period as well as over the course of the 
disease using a retrospective cohort of patients aged 50+ in the UK General Practice 
Research Database. Each patient was matched to another without COPD on year of 
birth, sex, general practice and completed years of medical records up to at least a 
year after the index date for COPD between 1990 and 1998. We identiﬁ ed 24,000 
such pairs that also satisﬁ ed a requirement for at least one medical consultation and 
at least one prescription for any drug in the year prior to the index date for COPD. 
RESULTS: Based on trends in rate ratios, we found signiﬁ cant time-dependent associa-
tions between the incident COPD diagnosis and incident comorbid conditions such as 
lung cancer, myocardial infarction, pneumonia, cardiac disorders, osteoporosis, frac-
tures, skin bruises, psychiatric disorders and respiratory infections. CONCLUSIONS: 
The results indicated interesting associations which could help improve our under-
standing of the natural history of COPD and its burden. This methodology can be 
used to identify important comorbidities for effective comparative assessments.
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OBJECTIVES: The objective of this study was to estimate the effectiveness of vareni-
cline, bupropion and nicotine replacement therapy (NRT) in smoking cessation in two 
specialized smoking units belonging to primary care centers. METHODS: A multi-
center longitudinal observational study was designed. Patient’s data were collected 
retrospectively based on their clinical records. Patients over the age of 18, who initi-
ated treatment of smoking cessation between January 1, 2006 and January 12, 2008 
with varenicline, bupropion or NRT were included in the analysis. Patient’s follow-up 
was conducted from time-baseline (day 1) and assessed at 6 and 12 months. Main 
variables included in the study were: comorbidities, effectiveness (continuous absti-
nence) and pharmacological tolerability. Statistical analysis was performed by Kaplan-
Maier survival curves; P < 0.05. RESULTS: A total of 957 smokers patients treated 
with NRT (53.0%), bupropion (25.1%) and varenicline (21.9%) were included in the 
analysis. The mean age of participants was 47.6 (11.3) years and 58.6% were men. 
The average duration of smoking was 19.5 (6.7) years. At 6 months, 61.2% (95% 
CI: 54.6–67.8%) of participants in the varenicline group were continuously abstinent 
from smoking compared with 56.9% (95% CI: 50.6–63.2%) in the bupropion group 
and 52.3% (95% CI: 48.0–56.6%) in the NRT group; p = 0.003. At 12 months, the 
rate of continuous abstinence was 57.4% (95% CI: 50.7–64.1%) in the varenicline 
group compared with 52.9% (95% CI: 46.6–59.2%) in the bupropion group and 
47.1% (95% CI: 42.8–51.4%) in the NRT group; p = 0.002. Pharmacological toler-
ability was similar between groups except for symptoms of irritability which were 
lower in the varenicline group: 4.3% compared to 8.3% in the bupropion group and 
10.3% in the NRT group. CONCLUSIONS: Varenicline appeared to be an effective 
and safety alternative compared with bupropion and NRT on smoking cessation in 
the primary care setting.
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OBJECTIVES: Use of triple therapy (long-acting beta2 agonist [LABA], inhaled corti-
costeroid [ICS] and long-acting muscarinic antagonist [LAMA]) for the treatment of 
COPD has doubled in the UK over the past 5 years for all severities of the disease. 
This research was designed to compare the two most commonly prescribed combina-
tion inhalers (BUD/FORM and SALM/FLU) as the basis of triple therapy with TIO, 
the most widely used LAMA. METHODS: Systematic review of CENTRAL, EMBASE 
and MEDLINE for randomised controlled trials (RCTs) in patients with COPD treated 
with BUD/FORM+TIO or SALM/FLU+TIO was conducted in May 2010. Mixed 
treatment comparison (MTC) using TIO as a common comparator was conducted 
using a Bayesian Markov Chain Monte Carlo simulation. Fixed- and random-effects 
models were explored with the preferred model selected based on the Deviance Infor-
mation Criterion (DIC). Data was extracted from relevant trials on severe exacerba-
tions (a composite of oral corticosteroids, hospitalizations and A&E visits due to 
worsening symptoms). Summary effect estimate was calculated as odds ratio (OR) 
with 95% credible interval (95% CrI) where OR < 1 favoured BUD/FORM+TIO and 
OR > 1 favoured SALM/FLU+TIO. RESULTS: Of the 124 papers identiﬁ ed in the 
literature search, 3 RCTs had comparable patient populations and were able to supply 
data for analysis (1 BUD/FORM+TIO [N = 660] and 2 SALM/FLU+TIO [N = 301 
and N = 60]). The exclusion of papers was based on not meeting all of the following 
inclusion critieria: RCTs of the chosen comparators; COPD patient population; 
reporting exacerbations; English-language full publication; and non-duplicates. When 
the ﬁ xed- and random-effects MTC models were compared the ﬁ xed-effects MTC had 
the lowest DIC. The results indicate a 55% relative reduction in severe exacerbations 
with BUD/FORM+TIO compared to SALM/FLU+TIO (OR 0.45, 95% CrI: 0.22 to 
0.83). CONCLUSIONS: This MTC suggests that BUD/FORM-based triple therapy is 
signiﬁ cantly more effective at reducing severe exacerbations than SALM/FLU-based 
triple therapy.
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OBJECTIVES: Modeling a chronic disease like COPD is useful to extrapolate (inter-
mediate) treatment effects observed in short-term randomized trials to the medium or 
long term. This study aimed to extend an existing dynamic population model of COPD 
progression by including exacerbations and making the model stochastic. METHODS: 
The COPD model starts with COPD prevalence in the Dutch population speciﬁ ed by 
age, gender, disease severity (four severity stages) and smoking status. Each following 
year the model simulates the changes in the prevalence and COPD-related health care 
costs due to incidence, mortality and disease progression, i.e. annual decline in FEV1% 
predicted.The structure was adjusted to include moderate and severe exacerbations 
and the following input parameters were estimated by quantitative meta-analyses: the 
frequency, case-fatality, lung function decline, quality of life loss and costs of exacerba-
tions. The model was made stochastic by specifying probability distributions around 
all important model parameters. The adapted model can be used to assess the impact 
of interventions that inﬂ uence COPD incidence, disease progression, frequency and/or 
severity of exacerbations, mortality, quality of life or combinations of these effects. To 
illustrate the potential use of the model, long- term costs and effects were projected 
for four different COPD interventions, two on pharmacotherapy, one on smoking 
cessation therapy and one on pulmonary rehabilitation. RESULTS: Compared to a 
reference scenario representing minimal treatment, the cost-effectiveness of the four 
interventions ranged from c6,100 to c12,200 per QALY gained. The probability of 
the interventions to be cost-effective at a ceiling ratio of c20,000 varied from X to 
Y%. CONCLUSIONS: The extended COPD model can provide policy makers with 
information about long-term costs and effects of interventions over the entire chain, 
from primary prevention to care for very severe COPD. Moreover it describes the 
uncertainty of the outcomes.
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OBJECTIVES: This study compared efﬁ cacy and safety of ciclesonide (CIC) with 
ﬂ uticasone (FP) in the treatment of bronchial asthma. METHODS: Comparison was 
based on randomized controlled trials (RCTs) identiﬁ ed by means of systematic 
review, carried out according to the Cochrane Collaboration guidelines. The most 
important medical databases (EMBASE, MEDLINE, CENTRAL) were searched. Two 
reviewers independently selected trials, assessed their quality and extracted data. 
Meta-analysis of head-to-head trials was performed. RESULTS: Ten RCTs directly 
comparing CIC vs. FP were identiﬁ ed and included in the analysis. Comparisons of 
both interventions in 1:1 and 1:2 dose ratios were assessed in 8 and 5 trials, respec-
tively. Efﬁ cacy of CIC was comparable to FP in both, 1:1 and 1:2 dose ratios with 
respect to reduction in risk of asthma exacerbations, improvement in proportion of 
symptom-free days, rescue medication-free days and improvement in asthma symp-
toms. Moreover, CIC and FP showed similar improvement in spirometric parameters. 
Comparison between CIC and FP in 1:1 dose ratio revealed that treatment with CIC 
was associated with statistically signiﬁ cant risk reduction of adverse events possibly 
related to study medication (RR = 0.57 [0.39; 0.83]; NNT = 16.89 [10.24; 48.18]) 
and candidosis (RR = 0.31 [0.17; 0.56], NNT = 32.74 [22.23; 61.99]), while the 
differences between groups were not signiﬁ cant for 1:2 dose ratio. There were no 
statistically signiﬁ cant differences between CIC and FP in either dose ratio with respect 
to the risk of any adverse events, upper respiratory tract infections, pharyngitis and 
dysphonia. CONCLUSIONS: Ciclesonide is a therapeutic option for patients with 
bronchial asthma showing comparable efﬁ cacy to ﬂ uticasone in both 1:1 and 1:2 dose 
ratios and provides concomitant risk reduction of candidosis and adverse events 
related to study medication.
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OBJECTIVES: This study compared efﬁ cacy and safety of ciclesonide (CIC) with 
budesonide (BUD) in the treatment of bronchial asthma. METHODS: Comparison 
was based on randomized controlled trials (RCTs) identiﬁ ed by means of systematic 
review, carried out according to the Cochrane Collaboration guidelines. The most 
important medical databases (EMBASE, MEDLINE, CENTRAL) were searched. Two 
